New Study Shows Promise for Migraine Relief with Cannabis
A recent study has raised hopes for those suffering from migraines. Conducted by researchers and presented at the American Headache Society Annual Meeting, this investigation suggests that inhaling a specific combination of CBD and THC may provide effective and swift relief from migraine symptoms.
Dr. Nathaniel M. Schuster, a neurologist specializing in pain and headaches at UC San Diego’s Analgesic Medical Center, emphasized that this research marks the first controlled study of its kind in this area. He noted, “This is compelling evidence regarding the anti-migraine effects of cannabis on humans.”
In the study, 92 patients—primarily women with an average age of 41—were administered varying combinations of 6% THC, 11% CBD, a mix of both, or a placebo. Results showed that around 67.2% of those receiving the THC/CBD combination experienced pain relief within two hours, compared to 46.6% in the placebo group. Furthermore, about 34.5% of patients in the THC/CBD group reported complete pain relief during this period, as opposed to 15.5% in the placebo group.
Interestingly, patients noted ongoing pain relief for up to 24 hours, with some experiencing relief lasting as long as 48 hours. Schuster mentioned that while individuals in the THC-only group did report feeling slightly high, there were no significant adverse effects.
He explained that CBD is known to mitigate the psychoactive side effects of THC, likely making the combination beneficial for migraine treatment. Yet, he cautioned that participants received a carefully monitored dosage. “Many neurologists, including myself, are concerned about potential medication overuse headaches from frequently using cannabinoids,” he remarked.
Schuster advised that patients limit their use to fewer than 10 times a month, suggesting it should ideally be used for migraines that do not respond to traditional treatments. The popularity of cannabis has surged recently. Currently, 38 states and Washington, D.C., have legalized it for medical purposes, with 24 of those allowing recreational use for individuals over 21.
Recent findings indicate that cannabis may also alleviate chronic pain, reduce muscle spasms, and help with appetite stimulation in patients undergoing treatments such as chemotherapy. However, amid its potential benefits, new research points to risks including adverse effects on cardiovascular health, mirroring the risks associated with smoking.
Compounding the complexity, some studies suggest that cannabis use might increase the likelihood of heart attacks and strokes, particularly among older adults. Additionally, altering of brain dopamine activity linked to cannabis use has raised concerns similar to those observed in psychosis.
Dr. Ken Weinberg, a cannabis specialist in New York, highlighted challenges related to cannabis research due to its classification as a Schedule I drug since 1970, making rigorous studies difficult. “I don’t think there’s enough data yet,” he noted, calling for more comprehensive research.
